Efficacy of the tyrosine kinase inhibitor gefitinib in a patient with metastatic small cell lung cancer
- 1 April 2005
- journal article
- case report
- Published by Elsevier in Lung Cancer
- Vol. 48 (1) , 141-144
- https://doi.org/10.1016/j.lungcan.2004.10.012
Abstract
No abstract availableKeywords
This publication has 6 references indexed in Scilit:
- EGFR Mutations in Lung Cancer: Correlation with Clinical Response to Gefitinib TherapyScience, 2004
- Activating Mutations in the Epidermal Growth Factor Receptor Underlying Responsiveness of Non–Small-Cell Lung Cancer to GefitinibNew England Journal of Medicine, 2004
- Efficacy of Gefitinib, an Inhibitor of the Epidermal Growth Factor Receptor Tyrosine Kinase, in Symptomatic Patients With Non–Small Cell Lung CancerJAMA, 2003
- Multi-Institutional Randomized Phase II Trial of Gefitinib for Previously Treated Patients With Advanced Non–Small-Cell Lung CancerJournal of Clinical Oncology, 2003
- Selective Oral Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor ZD1839 Is Generally Well-Tolerated and Has Activity in Non–Small-Cell Lung Cancer and Other Solid Tumors: Results of a Phase I TrialJournal of Clinical Oncology, 2002
- In vitro invasion of small-cell lung cancer cell lines correlates with expression of epidermal growth factor receptor.British Journal of Cancer, 1998